Investigational drug · Phase 2
Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab"
First trial start
2024
Sep 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Non-squamous Non-small-cell Lung Cancer
- Advanced Squamous Non-Small Cell Lung Carcinoma
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Squamous Non-Small Cell Lung Carcinoma
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage III
- Non-small Cell Lung Cancer Stage IV
- Non-small Cell Lung Cancer Recurrent
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab" as an intervention, largest first.
- A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant MetastasesPivotal-lookingRecruiting
Rakuten Medical, Inc.Industry
NCT06699212 · 412 participants (planned) · Start Dec 24, 2024 · Primary completion Sep 2028
Drug: Pembrolizumab; Carboplatin and 4 more · For: Recurrent Head and Neck Squamous Cell Carcinoma
Sites: Duarte, California; Miami, Florida; Tampa, Florida · 22 sites in all
- Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerPivotal-lookingRecruiting
Genelux CorporationIndustry
NCT06463665 · 142 participants (planned) · Start Sep 26, 2024 · Primary completion Feb 2027
Drug: Olvimulogene nanivacirepvec; Platinum chemotherapy: carboplatin or cisplatin and 3 more · For: Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer and 5 more
Sites: Bullhead City, Arizona; Clermont, Florida; Coral Springs, Florida · 15 sites in all
- TATE and Pembrolizumab (MK3475) in mCRC and NSCLCPivotal-lookingRecruiting
Teclison Ltd.Industry
NCT04701476 · 110 participants (planned) · Start May 20, 2021 · Primary completion Mar 31, 2027
Drug: TATE and pembrolizumab; TAS-102 pill and 1 more · For: Colorectal Cancer; Lung Cancer
Sites: Orange, California; Hsinchu, Taiwan; Taichung, Taiwan
- MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.Pivotal-lookingRecruiting
Swiss Cancer InstituteAcademic, hospital or other
NCT07574047 · 108 participants (planned) · Start Oct 12, 2026 · Primary completion Jun 2030
Drug: Immune Checkpoint Inhibitors; Immune Checkpoint Inhibitors · For: Melanoma; Advanced Melanoma
Sites: Fribourg, Switzerland; Basel, Switzerland; Bellinzona, Switzerland · 9 sites in all
- Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.Status unknown
MultiVir, Inc.Industry
NCT03544723 · 40 participants (planned) · Start Oct 1, 2018 · Primary completion Jun 30, 2022
Drug: Ad-p53 · For: Solid Tumor; Lymphoma
Sites: Chicago, Illinois; Morristown, New Jersey · 3 sites in all
Peking Union Medical College HospitalAcademic, hospital or other
NCT06388031 · 27 participants (planned) · Start Aug 9, 2024 · Primary completion Jan 10, 2027
Drug: Immune checkpoint inhibitor · For: Non-small Cell Lung Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Non-squamous Non-small-cell Lung Cancer
- Olvi-Vecolvimulogene nanivacirepvec, GL-ONCPhase 33 trials
Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer
- JAB-3312Phase 32 trials
Allist Pharmaceuticals, Inc. · KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.